← CATALYST PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $500k |
$102.3m
+20361.27%
|
$118.7m
+16.06%
|
$140.8m
+18.61%
|
$214.2m
+52.10%
|
$398.2m
+85.90%
|
$491.7m
+23.49%
|
$589.0m
+19.78%
|
$597.0m
+1.35%
|
|
| Cost of Revenue | — | — | $19.9m |
$14.8m
-25.90%
|
$17.0m
+15.45%
|
$21.9m
+28.43%
|
$34.4m
+57.16%
|
$52.0m
+51.10%
|
$68.8m
+32.48%
|
$87.3m
+26.74%
|
$83.8m
-3.94%
|
|
| Cost of sales | — | — | $19.9m |
$14.8m
-25.90%
|
$17.0m
+15.45%
|
$21.9m
+28.43%
|
$34.4m
+57.16%
|
$52.0m
+51.10%
|
$68.8m
+32.48%
|
$87.3m
+26.74%
|
$83.8m
-3.94%
|
|
| Gross Profit (Calculated) (derived) | — | — | ($19.4m) |
$87.5m
+550.83%
|
$101.7m
+16.17%
|
$118.9m
+16.96%
|
$179.8m
+51.17%
|
$346.2m
+92.56%
|
$422.9m
+22.14%
|
$501.7m
+18.64%
|
— | |
| Research and Development Expense | $11.4m | $11.4m | $19.9m | $18.8m | $16.5m | $16.9m | $19.8m | $93.2m | $12.6m | $12.7m | $11.5m | |
| Selling, General and Administrative Expense | — | — | $15.9m | $36.9m | $44.2m | $49.6m | $58.2m | $133.7m | $177.7m | $193.8m | $196.2m | |
| Amortization of Intangible Assets | — | — | — | — | — | $0 | $1.1m | $32.6m | $37.4m | $37.5m | — | |
| Operating Expenses | $19.3m | $18.7m | $35.8m | — | — | — | — | — | $190.4m | $206.5m | $245.5m | |
| Total operating costs and expenses | $19.3m | $18.7m | $35.8m | $70.5m | $77.8m | $88.4m | $112.4m | $311.4m | $296.6m | $331.2m | — | |
| Operating Income (Loss) | ($19.3m) |
($18.7m)
+3.11%
|
($35.3m)
-88.95%
|
$31.8m
+190.16%
|
$41.3m
+29.79%
|
$52.4m
+26.83%
|
$101.8m
+94.40%
|
$86.8m
-14.75%
|
$195.1m
+124.77%
|
$257.8m
+32.11%
|
$267.6m
+3.83%
|
|
| Unrealized gain (loss) on available-for-sale securities, net of tax of $0, ($20) and $4, respectively | — | — | ($20k) | $30k | $22k | ($179k) | $172k | ($10k) | $50k | ($64k) | — | |
| Other Nonoperating Income (Expense) | $322k | $454k | $1.3m | $1.6m | $587k | $282k | $2.9m | $7.7m | $21.1m | $25.7m | — | |
| Other income, net | $322k | $454k | $1.3m | $1.6m | $587k | $282k | $2.9m | $7.7m | $21.1m | $25.7m | $3.1m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($18.1m) | ($18.4m) | ($34.0m) | $33.4m | $41.9m | $52.7m | $104.7m | $94.5m | $216.3m | $283.5m | $296.5m | |
| Income tax provision | $0 | $0 | $0 | $1.5m | ($33.1m) | $13.2m | $21.6m | $23.1m | $52.4m | $69.2m | — | |
| Current Income Tax Expense (Benefit) | — | — | — | $1.5m | ($122k) | $3.9m | — | — | — | $76.0m | $75.1m | |
| Net Income (Loss) Attributable to Parent | ($18.1m) |
($18.4m)
-1.88%
|
($34.0m)
-84.68%
|
$31.9m
+193.74%
|
$75.0m
+135.24%
|
$39.5m
-47.35%
|
$83.1m
+110.42%
|
$71.4m
-14.05%
|
$163.9m
+129.50%
|
$214.3m
+30.78%
|
$221.3m
+3.26%
|
|
| Earnings Per Share, Basic | — | — | ($0.33) | $0.31 | $0.72 | $0.38 | $0.80 | $0.67 | $1.38 | $1.75 | $1.80 | |
| Earnings Per Share, Diluted | ($0.22) | ($0.21) | ($0.33) | $0.30 | $0.71 | $0.37 | $0.75 | $0.63 | $1.31 | $1.68 | $1.73 | |
| Basic | — | — | $102,633,884.00 | $102,944,316.00 | $103,512,913.00 | $103,379,349.00 | $103,374,606.00 | $106,279,736.00 | $118,457,673.00 | $122,290,866.00 | $1.80 | |
| Diluted | — | — | $102,633,884.00 | $106,020,936.00 | $106,242,273.00 | $107,795,585.00 | $111,375,631.00 | $113,753,154.00 | $124,943,603.00 | $127,257,929.00 | $221,323,000.00 | |
| Additional Financial Items | ||||||||||||
| Selling Expense | — | — | — | — | — | — | — | — | $118.7m | $130.7m | — | |
| Comprehensive income | — | ($18.4m) | ($34.0m) | $31.9m | $75.0m | $39.3m | $83.3m | $71.4m | $163.9m | $214.3m | — |